lanadelumab-flyo

lanadelumab-flyo (TAKHZYRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

TAKHZYRO is a marketed brand name for lanadelumab-flyo. Check FDA Drugs@FDA for the current US label holder and prescribing information.

lanadelumab-flyo has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.